A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes.
The protein is a key regulator of many mitochondrial functions, as well as of the cell as a whole.
Published in Nature Cell Biology (NCB), the study shows that the EXD2 protein is critical for the mitochondria, the cell’s powerhouses, to produce energy.
This protein was previously thought to be located in the cell nucleus and to be involved in DNA repair.
The results contribute to our basic understanding of mitochondria and suggest that EXD2 could be important for fertility and represent a potential target for cancer therapy.
Researchers at IRB Barcelona unravel the role of the histone BigH1 in the development of male sex cells from stem cells.
The study, which was performed in Drosophila melanogaster, paves the way to a greater understanding of male infertility.
Published in Cell Reports, the work sheds light on the mechanisms through which histones regulate how stem cells give rise to differentiated cells.
Xavier Salvatella, ICREA researcher at IRB Barcelona, proposes a new approach to combat prostate tumour cells that have become unresponsive to the treatments currently available.
The incidence of prostate cancer is increasing worldwide. In the US and Europe, it is one of the most common tumours and among the main causes of death by cancer.
A study published by IRB Barcelona in Nature Genetics demonstrates that the error (mutation) surveillance and repair system shows greater efficiency in the protein-coding regions of genes.
A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.
This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.
Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.
Researchers at IRB Barcelona reveal the capacity of epithelial-derived tumours to grow in the absence of a microenvironment.
Featured on the cover of the journal Proceedings of the National Academic of Sciences (PNAS), the study identifies the cell types and molecular mechanism involved in tumour initiation and growth.
The results of this study contribute to our understanding of the internal mechanisms of the tumour, which may provide a therapeutic target.
Genomic instability is the main risk factor for tumour development in humans. Therefore understanding its origin and exploring therapeutic targets is paramount.
Histone 1 silences a region of the genome that causes irreparable DNA damage when translated and is lethal for the organism.
Stem cell functions continue to be governed by day and night cycles (circadian rhythms) during ageing, but their rhythms become devoted to tissue repair and not to the maintenance of tissue tone.
The two studies published in Cell and headed by Salvador Aznar Benitah at IRB Barcelona reject the scientific dogma associating ageing with the loss of stem cell circadian rhythm.
A low-calorie diet delays alterations in the rhythmic functions of stem cells and slows down ageing.
Fran Supek (IRB Barcelona) and Ben Lehner (CRG) identify important processes that create mutations that cause cancer by studying the genomes of more than 1,000 tumors.
Many mutations in human cancers are caused by mistakes made by a repair mechanism or ‘DNA spellchecker’ rather than the actual damage to DNA caused by the environment.
Sunlight and alcohol consumption increase the rate at which this happens, resulting in more mutations in the most important parts of our genomes.